Journal of Clinical Oncology
Articles in this Issue
CAREFOL: A phase 3, randomized, open-label, multicenter trial of camrelizumab and rivoceranib with or without intravenous FOLFOX chemotherapy as first-line treatment for unresectable hepatocellular carcinoma.
TPS4257 Background: The combination of camrelizumab (an anti-PD-1 IgG4 monoclonal antibody) and rivoceranib (a VEGFR2-TKI)...
Differences in treatment outcomes among <i>EGFR</i> mutations, fusion oncogenes, and other actionable alterations in NSCLC: A large Japanese real-world cohort.
e20712 Background: Molecular targeted therapies have transformed the management of non–small cell lung cancer (NSCLC) with...
Clinical impact of <i>TOP1</i> alterations on outcomes to topoisomerase-I–directed therapies across chemotherapy and antibody-drug conjugates.
e15044 Background: Topoisomerase-I (TOP1)–directed therapies are used broadly in solid tumors, including irinotecan-based...
Neoadjuvant therapy versus upfront surgery for resectable/borderline resectable pancreatic ductal adenocarcinoma: Systematic review and meta-analysis of randomized controlled trials.
e16461 Background: Neoadjuvant strategies are becoming increasingly popular in resectable and borderline resectable pancre...
Zongertinib in HER2-altered colorectal cancer: A pooled analysis of colorectal cancer patients from two clinical trials.
3538 Background: Zongertinib, an irreversible TKI, selectively inhibits HER2 while sparing wild-type EGFR, thereby minimiz...
Lorlatinib vs crizotinib as first-line treatment for advanced <i>ALK</i> + non-small cell lung cancer: 7-year update from the phase 3 CROWN study.
8502 Background: Median progression-free survival (PFS) was not reached (NR) with lorlatinib in the phase 3 CROWN study af...
A prospective study of tumor-informed ctDNA minimal residual disease detection in bone and soft tissue sarcomas.
3057 Background: The high recurrence and metastasis rates lead to poor survival of patients with sarcoma. Conventional ima...
A phase III randomized study comparing BCD-201, a pembrolizumab biosimilar candidate, and reference pembrolizumab in patients with advanced melanoma.
9541 Background: The development of clinically comparable biosimilars of key immuno-oncology agents is essential to improv...
Social determinants of health (SDOH) and barriers to allogeneic hematopoietic stem cell transplantation (HCT) in acute myeloid leukemia (AML) in a community setting.
e13519 Background: HCT is curative for patients with intermediate- or adverse-risk AML; however, timely referral to transp...
Pathologic nodal burden in TAILOR-RT–eligible breast cancer: An NCDB analysis informing regional therapy de-escalation.
e12616 Background: The optimal extent of axillary management in patients with biologically low-risk, node-positive breast...
Association between tumor mutation status, pretreatment weight change, and overall survival in metastatic non–small cell lung cancer.
e24075 Background: Unintentional weight loss is common in non–small cell lung cancer (NSCLC) and has been correlated with...
Comparison of cisplatin/gemcitabine or carboplatin/gemcitabine on efficacy, toxicity, and quality of life from the randomized DISCUS trial.
4583 Background: The DISCUS trial compared 3 versus 6 cycles (3C versus 6C) of chemotherapy followed by avelumab in 267 pa...
Sintilimab combined with short-course intensified chemotherapy regimen nab-POF in the treatment of metastatic gastric cancer (FDZL-GC002): A single-arm, phase 2 trial.
4057 Background: This prospective phase II study investigates a novel therapeutic strategy combining PD-1 inhibitor sintil...
Proteolysis-targeting chimera (PROTAC) targeting BTK degradation for cancer therapy in mantle cell lymphoma.
e19045 Background: Mantle cell lymphoma (MCL) is characterized by Bruton tyrosine kinase (BTK)-signaling which activates t...
Exploratory analysis of prognostic value of ctDNA monitoring among advanced breast cancer with oligometastatic disease: An ancillary biomarker study of JCOG 2110 (JCOG2110A1).
TPS1158 Background: Oligometastatic advanced breast cancer represents a biologically heterogeneous disease state in which...
Cancer cachexia and symptomatic toxicity among 706 older adults with advanced cancer receiving treatment: A URCC NCORP nationwide study.
12067 Background: Cancer cachexia is a severe wasting condition characterized by rapid weight loss. Its impact on symptoma...
Neoadjuvant serplulimab plus nab-paclitaxel and SOX in locally advanced gastric or gastroesophageal junction adenocarcinoma: An interim analysis of a multicenter, randomized, double-blind, phase II trial.
e16131 Background: Despite standard neoadjuvant chemotherapy and radical resection, patients with locally advanced gastric...
Lymph node ratio and patterns of recurrence in oral squamous cell carcinoma treated with surgery and adjuvant concurrent chemoradiotherapy.
e18084 Background: Despite curative surgery and adjuvant concurrent chemoradiotherapy (CCRT), a subset of patients with or...
Treatment patterns and outcomes with olutasidenib after venetoclax in IDH1-mutated AML using real-world data from a chart review.
e18527 Background: Olutasidenib (OLU), a selective oral inhibitor of mutant IDH1 (m IDH1...
Beamion BCGC-1: Four new phase Ib/II cohorts to evaluate oral zongertinib with other agents in HER2-positive metastatic breast cancer (mBC) and metastatic colorectal cancer (mCRC).
TPS3177 Background: Zongertinib, an oral, irreversible TKI, selectively inhibits HER2 while sparing wild-type EGFR, thereb...
Contribution of atezolizumab (atezo) to the efficacy of the zanzalintinib (zanza) + atezo combination in patients (pts) with previously treated metastatic colorectal cancer (mCRC): Evidence from the phase 3 STELLAR-303 trial.
3574 Background: Outcomes remain poor for pts with previously treated mCRC, the vast majority of whom have tumors that are...
Toxicity risk calculator for personalised prediction of irAEs in patients with solid tumours receiving ICIs, developed based on a clinical dataset and machine learning approaches.
1628 Background: Immune checkpoint inhibitors (ICIs) can cause severe (grade 3-4) immune-related adverse events (irAEs), w...
Impact of oral SERDs, including giredestrant, on survival in HR+ HER2− metastatic breast cancer: A meta-analysis.
1084 Background: Oral selective estrogen receptor degraders (SERDs) are designed to overcome endocrine resistance in HR+ H...
Stage gap and projected metastatic surge for young-onset colorectal cancer: A decade-long call to action.
e15702 Background: By 2023,1 in 10 colon cancers and 1 in 4 rectal cancers will occur under age 50. Young-onset colorectal...
Does treatment sequencing matter in stage IV NSCLC with brain metastases? A National Cancer Database study.
e20657 Background: The optimal sequencing of brain-directed radiation and systemic therapy in stage IV NSCLC with brain me...